Rita Medical Systems Launches OmniPICC PI(TM) Power Injectable Peripherally Inserted Central Catheter Product
28 Febrero 2006 - 5:30AM
PR Newswire (US)
Product Opens New Sales Opportunity; Designed for High-Flow Rate
Injections for Radiology Imaging and Interventions FREMONT, Calif.
and MANCHESTER, Ga., Feb. 28 /PRNewswire-FirstCall/ -- RITA Medical
Systems, Inc. (NASDAQ:RITA), a publicly traded medical device
company focused solely on cancer therapies, today announced the
introduction of the OmniPICC PI(TM), a power injectable
peripherally inserted central catheter (PICC). The OmniPICC is
designed to allow clinicians to inject patients at high-flow rates
of up to 5ml/sec at power injection settings of 300psi for the
delivery of contrast media used to enhance the visualization of
blood vessels and other biological structures during radiological
imaging and interventional procedures. The OmniPICC, now available
in the United States, complements the Company's existing line of
specialty access catheter products. The OmniPICC received 510(k)
marketing clearance from the U.S. Food and Drug Administration
(FDA) in November 2005 and has been in limited market release since
January 2006. The Company is pursuing the CE mark for the product
for distribution in Europe. Joseph DeVivo, President and CEO of
RITA Medical Systems, commented, "We believe the OmniPICC is an
important addition to our line of infusion products because it is
expected to allow RITA to participate in what we believe is the
fastest growing market segment in vascular access. The sale of
power injectable PICC lines is also expected to be incremental to
our existing business." Mr. DeVivo continued, "I expect the
OmniPICC to help our sales team grow our specialty access catheter
business in both existing and competitive accounts." Conventional
PICC lines are routinely used for repeated and prolonged access to
the venous system. The OmniPICC differs from a conventional PICC
line by also allowing a physician to inject contrast media into a
patient's vascular system at high flow rates. High injection
pressures and flow rates are necessary to adequately disperse
contrast media throughout the body. The ability to use one catheter
for both venous access and to inject imaging contrast and other
high-flow rate agents in patients is expected to offer multiple
benefits including: patient comfort, patient safety and
convenience, and cost-savings for the healthcare provider system.
About RITA Medical Systems, Inc. RITA Medical Systems develops,
manufactures and markets innovative products for cancer patients
including radiofrequency ablation (RFA) systems for treating
cancerous tumors as well as percutaneous vascular and spinal access
systems. The Company's oncology product lines include implantable
ports, some of which feature its proprietary Vortex(R) technology;
tunneled central venous catheters; and safety infusion sets and
peripherally inserted central catheters used primarily in cancer
treatment protocols. The product line also includes the HABIB 4X
resection device which coagulates a "surgical resection plane" and
is designed to facilitate a fast dissection in order to minimize
blood loss and blood transfusion during surgery. The proprietary
RITA RFA system uses radiofrequency energy to heat tissue to a high
enough temperature to ablate it or cause cell death. In March 2000,
RITA became the first RFA Company to receive specific FDA clearance
for unresectable liver lesions in addition to its previous general
FDA clearance for the ablation of soft tissue. In October 2002,
RITA again became the first company to receive specific FDA
clearance, this time for the palliation of pain associated with
metastatic lesions involving bone. The RITA Medical Systems website
is at http://www.ritamedical.com/. The statements in this news
release related to the performance of the new OMNI PICC, physician
adoption of the OMNI PICC, and the technological achievements of
the OMNI PICC, the size of the market segment in vascular access
and the effect of the OMNI PICC on the Company's sales of specialty
access catheters are forward-looking statements involving risks and
uncertainties that could cause actual results to differ materially
from those is such forward-looking statements. Such risks and
uncertainties include bur are not limited to: market acceptance of
any new products or services of the Company; competitive pressures;
physician training efforts; the Company's dependence on its line of
specialty access catheters to achieve its sales goals and
profitability targets; the Company's historical and future
operating results and profitability; and general economic and
political conditions. Information regarding these risks is included
in the Company's filings with the Securities and Exchange
Commission. DATASOURCE: RITA Medical Systems, Inc. CONTACT: Stephen
Pedroff, VP Marketing Communications of RITA Medical Systems, Inc.,
+1-510-771-0400, or ; or media, Steve DiMattia, +1-646-277-8706, or
, or investors, Doug Sherk, , or Jennifer Beugelmans, both of EVC
Group, +1-415-896-6820, for RITA Medical Systems, Inc. Web site:
http://www.ritamedical.com/
Copyright
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Rita Medical (NASDAQ:RITA)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Rita Medical Systems (NASDAQ): 0 recent articles
Más de Rita Medical Systems (MM) Artículos de Noticias